Physician profile
Robert G Macgregor
NPI 1922201912
$49,223.77
in general payments reported to CMS, 2019-2025
82 companies · $4,640 in 2025
The $4,640 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,181 · 2020: $13K · 2021: $8,146 · 2022: $9,589 · 2023: $5,025 · 2024: $5,183 · 2025: $4,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,847.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23,196.92 | 2019-2025 | Kisunla, Amyvid |
| Emd Serono, INC. | $2,378.28 | 2019-2025 | Mavenclad |
| Abbvie INC. | $2,352.67 | 2021-2025 | |
| Biogen, INC. | $1,628.60 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $1,621.54 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Teva Pharmaceuticals USA, INC. | $1,239.17 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $1,144.02 | 2019-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $1,104.38 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $952.76 | 2020-2025 | Acthar |
| Sk Life Science, INC. | $914.03 | 2020-2025 | Xcopri |
| Pfizer INC. | $794.31 | 2019-2025 | |
| Neurelis, INC. | $715.05 | 2021-2025 | Valtoco |
| Allergan, INC. | $692.98 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $645.88 | 2019-2025 | Dysport |
| Genentech USA, INC. | $641.92 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Evrysdi |
Show all 80 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $615.62 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $533.34 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $506.05 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $493.64 | 2019-2025 | Uplizna, Aimovig |
| Jazz Pharmaceuticals INC. | $481.41 | 2019-2025 | Epidiolex |
| Alexion Pharmaceuticals, INC. | $476.60 | 2019-2025 | Ultomiris, Soliris |
| Catalyst Pharmaceuticals, INC. | $340.66 | 2020-2025 | Fycompa, Firdapse |
| Csl Behring | $340.44 | 2019-2025 | Hizentra |
| Merz Pharmaceuticals, LLC | $325.70 | 2021-2025 | Xeomin, Inbrija |
| Celgene Corporation | $314.65 | 2021-2025 | Zeposia |
| Tanabe Pharma America, INC. | $252.86 | 2019-2025 | Radicava |
| Octapharma USA, INC. | $249.30 | 2022-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Takeda Pharmaceuticals U.S.A., INC. | $220.16 | 2023-2025 | Hyqvia, Gammagard |
| Acadia Pharmaceuticals INC | $209.85 | 2019-2025 | Daybue |
| Vanda Pharmaceuticals INC. | $191.65 | 2024-2025 | Ponvory |
| Averitas Pharma INC. | $181.90 | 2024-2025 | Qutenza |
| Kyowa Kirin, INC. | $180.84 | 2020-2024 | Nourianz |
| Scilex Pharmaceuticals INC. | $171.17 | 2023-2024 | Ztlido |
| Biohaven Pharmaceuticals, INC. | $171.01 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $170.32 | 2023-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceutical Holding Company LTD. | $160.61 | 2022 | |
| Harmony Biosciences LLC | $157.24 | 2020-2023 | Wakix |
| Greenwich Biosciences, INC. | $147.81 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $146.21 | 2019 | |
| Tg Therapeutics, INC. | $146.11 | 2023-2025 | |
| Acorda Therapeutics, INC | $139.62 | 2019-2023 | Inbrija |
| Genzyme Corporation | $123.59 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $116.50 | 2021-2023 | Ponvory |
| Horizon Therapeutics Plc | $110.38 | 2021-2023 | Uplizna |
| Grifols USA, LLC | $91.48 | 2023-2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals LP | $82.28 | 2024-2025 | Wainua |
| Janssen Biotech, INC. | $79.34 | 2025 | |
| Merz North America, INC. | $79.10 | 2019-2020 | |
| Revance Therapeutics, INC. | $76.11 | 2025 | Daxxify |
| Sumitomo Pharma America, INC. | $72.90 | 2024 | Aptiom |
| Impel Pharmaceuticals INC. | $71.64 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $58.80 | 2025 | Symbravo |
| Aquestive Therapeutics, INC. | $57.27 | 2022 | |
| Boston Scientific Corporation | $56.92 | 2019-2024 | Watchman Flx |
| Avanir Pharmaceuticals, INC. | $54.49 | 2019-2022 | |
| Bausch Health US, LLC | $54.26 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $51.94 | 2019-2020 | |
| Hospira, INC. | $46.31 | 2022-2023 | |
| Livanova USA, INC. | $44.98 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Avion Pharmaceuticals | $41.07 | 2022 | |
| Ani Pharmaceuticals, INC. | $40.52 | 2023 | Purified Cortrophin Gel |
| Banner Life Sciences, LLC | $39.80 | 2022-2024 | |
| Mdd US Operations, LLC | $38.45 | 2019-2020 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $37.02 | 2019 | |
| Ge Healthcare | $36.80 | 2019 | |
| Promius Pharma LLC | $35.06 | 2019 | |
| Alnylam Pharmaceuticals INC. | $31.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.86 | 2020-2021 | |
| Sandoz INC. | $27.69 | 2024 | |
| Sarepta Therapeutics, INC. | $24.00 | 2023 | Exondys 51 |
| Supernus Pharmaceuticals, INC. | $23.73 | 2021 | |
| Amylyx Pharmaceuticals, INC. | $23.47 | 2023 | Relyvrio |
| Grt US Holding, INC. | $19.52 | 2022 | |
| Immedica Pharma US, INC. | $15.73 | 2024 | |
| Corium, LLC | $15.11 | 2023 | Azstarys |
| Akcea Therapeutics, INC. | $14.80 | 2019 | |
| Insightec,INC | $13.72 | 2024 | Exablate |
| Currax Pharmaceuticals LLC | $13.64 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.58 | 2025 | Crexont |
| Medtronic, INC. | $12.07 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Macgregor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.